ArticlePLoS pathogens2014
Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates.
Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 36 citations in OpenAlex.
- Animal modelling with theMicrobiology (Reading, England) · 2025Article
- Review
- Marmosets as models of infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Protective potential of outer membrane vesicles derived from a virulent strain ofFrontiers in microbiology · 2024Article
- The rLVS ΔHuman vaccines & immunotherapeutics · 2023Article
- Comparative evaluation of protective immunity againstFrontiers in cellular and infection microbiology · 2023Article
- Atomic Structure of IglD Demonstrates Its Role as a Component of the Baseplate Complex of themBio · 2022Article
- The O-Ag Antibody Response to Francisella Is Distinct in Rodents and Higher Animals and Can Serve as a Correlate of Protection.Pathogens (Basel, Switzerland) · 2021Article
- Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.Biomolecules · 2021Review
- Development, Phenotypic Characterization and Genomic Analysis of aFrontiers in microbiology · 2021Article
- Protective effects of the Francisella tularensis ΔpdpC mutant against its virulent parental strain SCHU P9 in Cynomolgus macaques.Scientific reports · 2019Article
- AFrontiers in microbiology · 2019Article
- Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.Scientific reports · 2018Article
- An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia.Journal of immunology research · 2018Article
- Adaptive Immunity toFrontiers in cellular and infection microbiology · 2018Review
- Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With VirulentFrontiers in cellular and infection microbiology · 2018Review
- An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia.Frontiers in microbiology · 2018Article
- Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles.PloS one · 2018Article
- Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis.PloS one · 2018Article
- Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis.Journal of visualized experiments : JoVE · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Francisella tularensis causes the disease tularemia. Human pulmonary exposure to the most virulent form, F. tularensis subsp. tularensis (Ftt), leads to high morbidity and mortality, resulting in this bacterium being classified as a potential biothreat agent. However, a closely-related species, F. novicida, is avirulent in healthy humans. No tularemia vaccine is currently approved for human use. We demonstrate that a single dose vaccine of a live attenuated F. novicida strain (Fn iglD) protects against subsequent pulmonary challenge with Ftt using two different animal models, Fischer 344 rats and cynomolgus macaques (NHP). The Fn iglD vaccine showed protective efficacy in rats, as did a Ftt iglD vaccine, suggesting no disadvantage to utilizing the low human virulent Francisella species to induce protective immunity. Comparison of specific antibody profiles in vaccinated rat and NHP sera by proteome array identified a core set of immunodominant antigens in vaccinated animals. This is the first report of a defined live attenuated vaccine that demonstrates efficacy against pulmonary tularemia in a NHP, and indicates that the low human virulence F. novicida functions as an effective tularemia vaccine platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.